{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
INN:loncastuximab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:iladatuzumab vedotin [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02605525: Phase 2 Interventional Withdrawn Immunoglobulin A Nephropathy
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:pegdarbepoetin beta [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03574545: Phase 1 Interventional Completed Rheumatoid Arthritis
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:eflenograstim alfa [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04055909: Phase 2 Interventional Active, not recruiting Shock, Septic
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03163446: Phase 2 Interventional Completed Staphylococcus Aureus Bacteremia
(2017)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:zamaglutenase [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00732082: Phase 1 Interventional Terminated Pancreatic Neoplasms
(2009)
Source URL:
Class:
PROTEIN
